Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab

NCT03340610 is registered in ClinicalTrials.gov with Southeast Retina Center, Georgia as lead sponsor.

NCT NCT03340610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab
Lead sponsor
Southeast Retina Center, Georgia
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2015
Completion date
December 12, 2018
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema